vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and Cheer Holding, Inc. (CHR). Click either name above to swap in a different company.

Cheer Holding, Inc. is the larger business by last-quarter revenue ($71.0M vs $45.1M, roughly 1.6× Amarin Corp plc). Cheer Holding, Inc. runs the higher net margin — 10.9% vs -23.3%, a 34.2% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs -0.1%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

AMRN vs CHR — Head-to-Head

Bigger by revenue
CHR
CHR
1.6× larger
CHR
$71.0M
$45.1M
AMRN
Growing faster (revenue YoY)
AMRN
AMRN
+7.1% gap
AMRN
7.0%
-0.1%
CHR
Higher net margin
CHR
CHR
34.2% more per $
CHR
10.9%
-23.3%
AMRN

Income Statement — Q1 FY2026 vs Q2 FY2025

Metric
AMRN
AMRN
CHR
CHR
Revenue
$45.1M
$71.0M
Net Profit
$-10.5M
$7.8M
Gross Margin
70.7%
Operating Margin
35.5%
11.7%
Net Margin
-23.3%
10.9%
Revenue YoY
7.0%
-0.1%
Net Profit YoY
33.0%
-37.5%
EPS (diluted)
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
CHR
CHR
Q1 26
$45.1M
Q4 25
$49.2M
Q3 25
$49.7M
Q2 25
$72.7M
$71.0M
Q1 25
$42.0M
Q4 24
$62.3M
Q3 24
$42.3M
Q2 24
$67.5M
$71.1M
Net Profit
AMRN
AMRN
CHR
CHR
Q1 26
$-10.5M
Q4 25
$-1.2M
Q3 25
$-7.7M
Q2 25
$-14.1M
$7.8M
Q1 25
$-15.7M
Q4 24
$-48.6M
Q3 24
$-25.1M
Q2 24
$1.5M
$12.4M
Gross Margin
AMRN
AMRN
CHR
CHR
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
70.7%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
73.4%
Operating Margin
AMRN
AMRN
CHR
CHR
Q1 26
35.5%
Q4 25
-12.9%
Q3 25
-22.4%
Q2 25
-22.0%
11.7%
Q1 25
-39.9%
Q4 24
-84.3%
Q3 24
-59.5%
Q2 24
-0.8%
16.4%
Net Margin
AMRN
AMRN
CHR
CHR
Q1 26
-23.3%
Q4 25
-2.5%
Q3 25
-15.6%
Q2 25
-19.4%
10.9%
Q1 25
-37.4%
Q4 24
-78.0%
Q3 24
-59.4%
Q2 24
2.3%
17.5%
EPS (diluted)
AMRN
AMRN
CHR
CHR
Q1 26
Q4 25
$0.00
Q3 25
$-0.02
Q2 25
$-0.03
$0.67
Q1 25
$-0.04
Q4 24
$-0.12
Q3 24
$-0.06
Q2 24
$0.00
$1.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
CHR
CHR
Cash + ST InvestmentsLiquidity on hand
$307.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$322.1M
Total Assets
$645.8M
$362.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
CHR
CHR
Q1 26
$307.8M
Q4 25
$302.6M
Q3 25
$286.6M
Q2 25
$298.7M
Q1 25
$281.8M
Q4 24
$294.2M
Q3 24
$305.7M
Q2 24
$306.7M
$186.1M
Stockholders' Equity
AMRN
AMRN
CHR
CHR
Q1 26
Q4 25
$459.3M
Q3 25
$458.9M
Q2 25
$464.9M
$322.1M
Q1 25
$473.7M
Q4 24
$486.2M
Q3 24
$531.4M
Q2 24
$551.9M
$286.1M
Total Assets
AMRN
AMRN
CHR
CHR
Q1 26
$645.8M
Q4 25
$670.8M
Q3 25
$659.8M
Q2 25
$670.1M
$362.7M
Q1 25
$655.7M
Q4 24
$685.3M
Q3 24
$750.6M
Q2 24
$799.9M
$333.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
CHR
CHR
Operating Cash FlowLast quarter
$3.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
CHR
CHR
Q1 26
Q4 25
$15.3M
Q3 25
$-12.7M
Q2 25
$16.6M
$3.9M
Q1 25
$-12.5M
Q4 24
$-13.3M
Q3 24
$-2.4M
Q2 24
$-2.7M
$-6.7M
Cash Conversion
AMRN
AMRN
CHR
CHR
Q1 26
Q4 25
Q3 25
Q2 25
0.51×
Q1 25
Q4 24
Q3 24
Q2 24
-1.81×
-0.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

CHR
CHR

Segment breakdown not available.

Related Comparisons